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Abstract
Background: Ibuprofen treatment of patent ductus arteriosus (PDA) has been shown to be as effective as
indomethacin in small randomized controlled trials, with possibly fewer adverse effects. However, adverse renal
effects of ibuprofen have been noted in some trials and suspected in our practice.
The purpose of this study was to examine whether ibuprofen and indomethacin treatment of PDA have
comparable effects on renal function as evidenced by urine output and serum creatinine.
Methods: Retrospective chart review of 350 patients. Serum creatinine and urine output were recorded prior to
start of treatment, during each course and after the last course of treatment. Pre-treatment mean creatinine and
urine output values were compared to treatment and post treatment means using 2-factor repeated measures
ANOVA.
Results: 165 patients were treated with indomethacin (2005-2006) and 185 received ibuprofen (2007-2008). There
was no difference between treatment groups in demographics or baseline renal function. For both groups, the
number of treatment courses was inversely correlated with birth weight and gestational age. Analysis of the first
course including all patients, revealed significant increase in creatinine and decrease in urine output with both
drugs, with a more pronounced effect of indomethacin on creatinine. In the subgroup of 219 patients who
received only one treatment course, there was a significant increase in creatinine after indomethacin, but not after
ibuprofen. In the 131 who received 2 or more courses, the decrease in urine output and increase in creatinine
were not different between drugs. There were significant decreases in urine output observed in the second and
third courses of ibuprofen treatment (both by 0.9 mL/kg/hr).
Conclusion: Both drugs have a similar short-term effect on renal function. Indomethacin had a more prominent
initial effect, while ibuprofen decreased renal function during the second and third courses similarly to
indomethacin. The changes in renal function seen with ibuprofen treatment should be considered in fluid and
electrolyte management, especially if treatment beyond one course is required.
Background
Patent ductus arteriosus (PDA) is a common occurrence
in very low birth weight (VLBW, ≤1500 g) infants,
which often causes significant morbidities. Left-to-right
shunting through the ductus may increase the risk of
intraventricular hemorrhage [1,2], necrotizing enteroco-
litis [3], bronchopulmonary dysplasia, and death [4,5].
Successful pharmacological closure of PDA with indo-
methacin was first reported in 1976, with subsequent
reports that indomethacin reduced neonatal morbidity
[6,7]. However, indomethacin may lead to complications
such as transient or permanent renal dysfunction [8,9],
necrotizing enterocolitis, and reduced cerebral oxygena-
tion [10]. These indomethacin-related complications
have prompted researchers to seek safer pharmacologi-
cal treatment for closure of PDA.
In recent years another cyclooxygenase inhibitor, ibu-
profen, has been proposed for the treatment of PDA,
and several randomized controlled trials have shown it
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adverse effects [11]. It is thought that ibuprofen is better
tolerated due to less effects on renal function, renal and
mesenteric blood flow [12-14], and cerebral blood flow
[15]. Adverse effects of ibuprofen have been noted in
some trials [16] and suspected in our practice. This dif-
ference might be due to the fact that the infants in the
previous trials were more mature (gestational age ~28
weeks) than the age of the infants at greatest risk for
PDA (younger than 26 weeks); thus, it is difficult to
extrapolate the clinical effects observed in those trials to
the younger and unselected population typically treated
in the clinical care context. Our primary objective was
to ascertain whether ibuprofen and indomethacin treat-
ment of PDA have comparable effects on renal function
as evidenced by urine output and serum creatinine, dur-
ing routine clinical usage.
Methods
Study design
This was a retrospective cohort study with a hypothesis
that ibuprofen and indomethacin treatment of PDA
have comparable effects on renal function as evidenced
by urine output and serum creatinine. In October 2006
Neonatology staff switched from indomethacin to ibu-
profen as the drug of choice for medical treatment of
PDA. The cohort of neonates treated with indomethacin
from January 2005 to October 2006 was compared to
those treated with ibuprofen from October 2006
through December 2008. The study was approved by
the Institutional Review Board of the Albany Medical
Center, and exempted from requiring informed consent.
Patient population
Records were reviewed for inborn or outborn preterm
neonates born at any gestation and birth weight,
admitted to the NICU of Albany Medical Center Hospi-
tal (New York State-designated Level IV Regional Peri-
natal Center) and requiring treatment for PDA, from
January 2005 through December 2008. The clinical
approach to the PDA was unchanged throughout the
study period and it is summarized here. Prophylactic
indomethacin was not used in our institution. Cardiol-
ogy consultation was requested if a symptomatic PDA
was suspected (extremely low birth weight neonate,
widened pulse pressures, murmur, bounding pulses, or
significant respiratory disease) and an echocardiogram
was performed. The size of the PDA was described qua-
litatively by the cardiologists (as absent, small, mild,
moderate, large, or synonymous terms), along with
blood flow direction. Attending neonatologists generally
initiated medical treatment if predominant left-to-right
shunting was noted through a PDA larger than “small”,
while also considering the patient’s clinical status,
expected course given postnatal age, and potential con-
traindications. The day after the last treatment dose was
administered, a follow-up echo was performed, and
another course of either ibuprofen or indomethacin was
given based on the same criteria used for the initial
course. The decision to use further courses of medical
treatment or resort to surgical ligation was made jointly
by the attending neonatologist, cardiologist and cardio-
thoracic surgeon. A mildly restrictive fluid therapy regi-
men was used, beginning with a weight-based guideline,
and then tailored to each infant’sc o n d i t i o na n dp o s t n a -
tal age. The fluid regimen was further restricted (by
approximately 20 mL/kg/day below the individualized
daily target) as cyclooxygenase inhibitor therapy was
initiated.
Indomethacin was dosed at 0.2 mg/kg/dose once, then
0.1 mg/kg/dose IV daily for 2 more doses for neonates
<750 g; 0.2 mg/kg/dose daily for 3 doses for neonates
750 g to 1 kg; and 0.2 mg/kg/dose every 12 hours for
those over 1 kg. Ibuprofen was dosed at 10 mg/kg/dose
once and then 5 mg/kg/dose daily for 2 more doses.
Data collected
Demographic data were recorded into an Excel spread-
sheet and de-identified. The s ed a t ai n c l u d e dg e n d e r ,
date of birth and date of discharge, birth weight, and
gestational age. PDA-related data recorded included:
date indomethacin or ibuprofen started, number of
courses of medical treatment given, whether PDA was
closed after the last treatment and whether surgical liga-
tion of the PDA was performed.
Renal function prior to, during and after medical
treatment of PDA was assessed by recording urine out-
p u ta n ds e r u mc r e a t i n i n e .S e r u mc r e a t i n i n eo nt h e
morning prior to administration of the first dose of ibu-
profen or indomethacin was used as the baseline level.
If no creatinine value was available from that day, the
one from the prior day was used. During each treatment
course, the last available serum creatinine was recorded.
Resolution of the drug effect on renal function was
assessed by evaluation of creatinine on the third to fifth
day after the last drug dose.
Evaluation of urine output was done on the same
schedule as creatinine, for 24 hours previous to, during
treatment, and three to five days after the last dose of
ibuprofen or indomethacin. Urine output was calculated
as mL/kg/hour.
Secondary outcomes noted were necrotizing enteroco-
litis (NEC), bronchopulmonary dysplasia (BPD), and
retinopathy of prematurity (ROP). NEC (defined using
Bell’s criteria [17]), spontaneous intestinal perforation
(defined using Vermont Oxford Network criteria [18]),
NEC-like illness, and whether NEC required surgical
intervention were recorded. NEC-like illness was defined
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appearance of bowel ischemia without pneumatosis or
portal gas on abdominal radiograph. BPD was defined as
oxygen requirement at 36 weeks post-menstrual age.
ROP exam and the stage of retinopathy were also evalu-
ated [19]. Presence of IVH and periventricular leukoma-
lacia (PVL) were recorded, as well as the stage of IVH
[20].
Sample size and statistical analysis
An a-priori power analysis setting the a error at 0.05
a n dße r r o ra t0 . 2 0r e v e a l e dt h a tam i n i m u mo f5 0
patients in each group was required to detect a 20% dif-
ference in urine output - well within the expected size
of the cohorts. SPSS for Windows (SPSS version 12.0.1,
Chicago, IL), as well as Minitab (Minitab version 15.0,
State College, PA) and Stata (Stata version 8, College
Station, TX) were used to conduct statistical data ana-
lyses. Pre-treatment mean creatinine and urine output
values were compared to treatment and post treatment
means using 2-factor repeated measures ANOVA (gen-
eralized linear model, including terms for treatment,
time, treatment-by-time interaction, and with patients
nested within treatment group). Dunnett’s post-hoc test
was used to compare within-group changes in mean
creatinine and urine output from baseline to each treat-
ment course. A p value of < 0.05 was considered
significant.
Chi-square analysis was performed to compare the
proportion of patients experiencing the secondary out-
comes of PDA closure, BPD, ROP, and NEC between
treatment groups.
In order to assess whether there is a difference in the
rate of PDA closure, number of doses of medical treat-
ment required, or changes in renal function depending
on gestational age or birth weight, these variables were
e v a l u a t e di ns u b g r o u pa n a l y s e s .G e s t a t i o n a la g ec a t e -
gories were divided into: <25 weeks, 25 0/7-27 6/7
weeks, 28 0/7 - 29 6/7 weeks, and ≥ 30 0/7 weeks. Birth
weight categories were divided into: ≤ 750 grams, 751
-1000 grams, 1001 - 1500 grams, and >1500 grams.
Results
Of the 350 patients, 165 were treated with indomethacin
and 185 received ibuprofen. The 7 cases where both
drugs were used were excluded from the analyses of
outcomes subsequent to the first course of treatment
[Table 1].
The overall efficacy was the same for ibuprofen (71%)
and indomethacin (68%) [Table 2]. The rate of ligation
overall was the same after treatment with indomethacin
and ibuprofen, with the exception of the neonates that
required 2 courses of treatment for PDA closure. More
babies required PDA ligation after receiving 2 courses of
indomethacin (53.7%) compared to ibuprofen (28.6%) (p
< 0.05) [Table 3].
Date of birth was considered as day of life one. There
was no difference in the initial treatment day between
indomethacin and ibuprofen [Table 4]. Second and third
treatment courses started at a median of one day after
conclusion of the previous course. There was, also, no
statistical difference in the intervals between first and
second (p = 0.2) or second and third treatment courses
(p = 0.4) [Table 4]. There was no difference between
drug treatment groups in gestational age, birth weight,
or baseline creatinine or urine output. We found a sig-
nificantly larger proportion of male infants in the ibu-
profen group (58% males; p = 0.04) [Table 1]. However,
ANOVA with gender as a covariate revealed no signifi-
cant gender effect on baseline urine output or creatinine
values, nor in their response to each treatment; cross-
tabulations revealed no statistically significant differ-
ences between genders in the number of treatment
courses, PDA closure or ligation rates in the ibuprofen
group (data not shown). The number of treatment
courses had a significant (p = 0.0001) inverse relation
with both birth weight and gestational age, in chi-square
analyses.
When all patients were included in the analysis of the
first treatment course, there was a statistically significant
Table 1 Baseline Population Characteristics
Indomethacin Ibuprofen
Birth Weight, grams (mean) 1048 1083
Birth Weight Categories, n (%)
≤ 750 grams 54 (33) 56 (30)
751 - 1000 grams 38 (23) 41 (22)
1001 - 1500 grams 51 (31) 54 (29)
> 1500 grams 22 (13) 35 (19)
Gestational Age, weeks (mean) 27.7 27.8
Gestational Age Categories, n (%)
< 25 weeks 33 (20) 34 (18)
25 - 27 6/7 weeks 61 (37) 68 (37)
28 - 29 6/7 weeks 35 (21) 37 (20)
≥ 30 weeks 36 (22) 47 (25)
Gender
Male 82 (50) 108 (58) *
Female 83 (50) 78 (42)
Number of courses, n (%) 165 185
1 101 (61) 118 (63)
2 41 (25) 28 (15)
3 19 (12) 37 (20)
4 4 (2) 2 (1)
Baseline urine output, mL/kg/h mean
(SD)
3.9 (1.4) 4.2 (1.6)
Baseline creatinine, mg/dL mean (SD) 0.96 (0.2) 0.93 (0.2)
PDA, patent ductus arteriosus
* denotes statistically significant difference between treatments, p < 0.05
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urine output (by 0.3 mL/kg/hr) from baseline, after
indomethacin [Figure 1][Table 5]. With ibuprofen treat-
ment, only the increase in creatinine was significant.
The ANOVA revealed that the increase in creatinine
was significantly greater with indomethacin than with
ibuprofen (p < 0.05 for both the treatment effect and
t h et r e a t m e n t - t i m ei n t e r a c t i o n )[ T a b l e5a n dF i g u r e1 ] .
However, there was no statistically significant difference
in the effect of both drugs on urine output.
In the subgroup of 219 patients who received only one
course of therapy, there was a significant increase in
creatinine (by 0.1 mg/dL, p = 0.001) after indomethacin,
but not after ibuprofen [Figure 2], with a significant
drug-by-time interaction (p = 0.029). Regarding urine
output, ANOVA revealed no significant differences
between drugs, although post-hoc tests showed a signifi-
cant decrease in urine output only in the indomethacin
group [Figure 2]. For the 131 neonates who received 2
or more total courses of treatment, there were signifi-
cant decreases in urine output and increases in
creatinine from baseline values, which were not signifi-
cantly different between drugs [Figure 2]. Post hoc ana-
lyses revealed significant decreases in urine output from
baseline observed during the last course of ibuprofen
treatment (both by 0.9 mL/kg/hr, p < 0.05), in the sub-
groups receiving 2 or 3 courses [Figure 2]. Creatinine
and urine output post-treatment returned to baseline
values in both groups, regardless of the number of
courses. Fluid intake was similar in both groups (data
not shown).
There was no difference in secondary outcomes
between the two drugs, except for ROP and NEC-like
illness. There was a significantly higher rate of ROP in
the indomethacin group [Table 2]. However, there was
no difference in the rate of severe ROP between the
groups. There was a significantly higher rate of NEC-
like illness in the indomethacin group (8% vs. 3% for
ibuprofen, p = 0.03); conversely, there was a trend
towards more frequent diagnosis of NEC in the ibupro-
fen group (8% vs. 4% for indomethacin, p = 0.08) [Table
2], but no difference in the rate of spontaneous
Table 2 Secondary Outcomes According to Treatment Group
Indomethacin Ibuprofen
(N = 161) (N = 182) p value
Day of Life at Start of Treatment (mean, SD) 3.3 ± 2.3 3.5 ± 2.7 NS
PDA Closed, n (%) 109 (68) 129 (71) 0.4
PDA Ligation, n (%) 45 (28) 38 (21) 0.1
BPD, n (%) 72 (45) 90 (49) 0.2
NEC-related conditions, any, n (%) 27 (17) 32 (18) 0.8
NEC, n (%) 6 (4) 15 (8) 0.08
NEC-Like Illness (%) 13 (8) 5 (3) 0.03*
Spontaneous Intestinal Perforations, n (%) 8 (5) 12 (7) 0.5
ROP, n (%) 65 (52) 41 (30) <0.001*
Severe ROP: Grades III-V 15 (12) 15 (11) 0.8
IVH, any, n (%) 58 (36) 57 (31) 0.4
Severe IVH: Grade III/IV 12 (8) 12 (9) 0.6
PVL 4 (2.4) 3 (1.6) 0.4
Death, n (%) 12 (7) 16 (9) 0.4
PDA, patent ductus arteriosus; BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; IVH, intraventricular
hemorrhage; PVL, periventricular leukomalacia.
The denominator for the percent (%) for each secondary outcome reflects the number of patients with evaluation of that outcome - for ROP in particular, 82
infants did not have a retinal exam.
* denotes statistically significant difference between treatments, p < 0.05
Table 3 Treatment Efficacy by Number of Treatment Courses
Indomethacin Ibuprofen
Number of Courses Used 1 2 3 1 2 3
Total N 101 41 19 118 28 37
PDA Closed, n (%) 89 (88.1) 18 (43.9) 3 (15.8) 108 (92.3) 15 (53.6) 7 (18.9)
PDA Ligations 8 (7.9) 22 (53.7)* 15 (78.9) 3 (2.6) 8 (28.6)* 26 (70.3)
PDA, patent ductus arteriosus.
Not all patients whose PDA remained open needed to have a surgical ligation.
* denotes statistically significant difference between treatments, p < 0.05.
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groups [Table 2].
Discussion
The purpose of this study was to examine whether ibu-
profen and indomethacin treatment of PDA have
comparable effects on renal function as typically used in
aN I C U ,w h e r ei ti sc o m m o nf o rE L B Wn e o n a t e st o
receive more than one course of cyclooxygenase inhibi-
tor therapy in order to close the PDA. In addition to
the renal effects, our observations on less common
potential adverse effects of cyclooxygenase inhibitors
add substantially to the available information on safety
of these therapies, as this is the largest comparison
study conducted in the US examining efficacy and side
effects.
Van Overmeire et al. studied the efficacy of indo-
methacin and ibuprofen given to larger premature
infants (≤32 weeks) at the age of 2-4 days. They
reported that the closure rate was similar (66% and 70%,
respectively) after the first course and that there was no
significant difference in side effects, although ibuprofen
was associated with significantly less impairment of
renal function [5]. The study showed that infants of
lower gestational age (<28 weeks) had a lower pharma-
cological closure rate and underwent surgical ligation
more frequently. This and several other studies
[11,13,21-23] found that there was similar efficacy in
PDA closure when using indomethacin or ibuprofen.
Most of these reports found that ibuprofen had fewer
side effects than indomethacin. However, these studies
enrolled small numbers of neonates, that were more
mature (mean gestational age >28 weeks) than those in
our study. Van Overmeire described 40 preterm infants
Table 4 Treatment Start Day
Indomethacin Ibuprofen
Initial Day of Treatment
Median 33
Mean 3.3 3.5
Minimum 11
Maximum 18 22
Interquartile range 22
Days between 1st and 2nd courses
Median 11
Mean 4.1 2.7
Minimum 11
Maximum 32 18
Interquartile range 20
Days between 2nd and 3rd courses
Median 11
Mean 1.9 2.6
Minimum 11
Maximum 91 3
Interquartile range 02
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Figure 1 Mean urine output and creatinine values for all patients by drug. Comparison of mean urine output and creatinine values for all
patients during the first course of therapy, by treatment drug. Indomethacin group (solid line) and Ibuprofen group (dashed line). PRE - pre-
treatment baseline; 1st - end of first course of treatment. * denotes statistically significant (p < 0.05) change from treatment baseline; § denotes
statistically significant (p < 0.05) difference in change from baseline between treatment groups.
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Page 5 of 9Table 5 Effect of Each Initial Treatment Course on Renal Function
Indomethacin Ibuprofen Comparison between treatments
on changes from baseline
(ANOVA)
Baseline 1st course p value for
change with
indomethacin
(t-test)
Baseline 1st course p value for
change with
ibuprofen
(t-test)
p value for
main
treatment
effect
p value for
treatment - time
interaction
Urine output
(mL/kg/hr; mean ± SD)
3.9 ± 1.4 3.6 ± 1.4 0.033 * 4.2 ± 1.6 4.0 ± 1.4 0.24 0.51 0.50
Serum Creatinine
(mg/dL; mean + SD)
0.96 ± 0.21 1.06 ± 0.24 <0.001* 0.93 ± 0.2 0.98 ± 0.24 0.005 * 0.039* 0.047 *
Supplemental analyses of the effect of each initial treatment course on renal function.
* denotes statistically significant (p < 0.05) change from baseline within a treatment group
Figure 2 Mean urine output and creatinine values by drug and number of courses. Comparison of mean urine output and creatinine
values by treatment drug for subgroups and defined by the total number of courses received. Left panel: patients who received only one
course of either ibuprofen or indomethacin. Middle panel: patients who received total of two courses. Right panel: patients who received 3 total
courses of medical treatment. Indomethacin group (solid line) and Ibuprofen group (dashed line). PRE - pre-treatment baseline; 1st - end of first
course of treatment, POST - 3-5 days after the last course of treatment. * denotes statistically significant (p < 0.05) change from baseline within a
treatment group. § denotes statistically significant (p < 0.05) difference in change from baseline between treatment groups.
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ment; only 7 required a repeat course [23]. Su et al.
compared efficacy and side effects of ibuprofen and
indomethacin in neonates (≤ 28 weeks) with echographi-
cally present PDA. They found both efficacy and side
effect profile to be the same in both groups, except for a
greater tendency toward oliguria after one course of
indomethacin compared to ibuprofen [16]. Because sur-
gical ligation was performed if the PDA was still present
after one course, that study does not elucidate effects on
renal function with further medical treatment.
The findings of our study confirm that indomethacin
has a more prominent initial effect on measures of renal
function than ibuprofen. However, ibuprofen had a det-
rimental effect on renal function in the second and
third courses equal to that of indomethacin. Both drugs
had a similar overall detrimental effect on renal func-
tion, with repeated courses.
Other recent studies support the notion that ibuprofen
therapy is not devoid of renal effects in neonates
[24-26]. Gournay et al. noted an increase in creatinine
in the prophylactic ibuprofen group and in those who
received a second course of ibuprofen, which resolved in
the second week of life. They also noted a decrease in
urine output with ibuprofen as compared with placebo
that returned to baseline after the first course. Ticker
and Yildirim described temporary oliguria and/or renal
dysfunction after treatment with one course of ibupro-
fen that is similar to that seen with indomethacin. Vieux
et al. found a significant decrease in glomerular filtra-
tion and tubular function impairment in the ibuprofen
g r o u pt h a tw a sn o ts e e ni nt h ep a t i e n t sw h od i dn o t
receive ibuprofen [25]. Richards et al. reported that the
effectiveness of ibuprofen in closing a PDA decreased
with a second course, and that creatinine was signifi-
cantly higher in neonates receiving a second course as
compared to controls [27].
Our study also adds information pertaining to the
safety of cyclooxygenase inhibitor treatment. There was
no difference in morbidities potentially associated with
cyclooxygenase inhibitor therapy between patients
receiving ibuprofen or indomethacin, except for the inci-
dence of ROP and NEC-like disease. These findings may
be incidental to secondary analyses, or they may hint at
clinically significant relationships. The higher rate of
ROP in the indomethacin group was related primarily to
higher incidence of stages 1 and 2 diseases, not of severe
ROP. This has not been seen in previous studies
[23,28,29]. It is possible that the difference in ROP rates
is related to the more stringent oxygen saturation tar-
gets implemented in 2006 [30].
In the ibuprofen group there was a trend towards a
higher frequency of NEC, but not of spontaneous intest-
inal perforations [Table 2]; NEC-like disease was
significantly less frequent. There was no increase in the
incidence of NEC seen in other studies of ibuprofen [5]
and this finding is unexpected since ibuprofen does not
significantly reduce mesenteric blood-flow velocity [13].
Diagnostic drift is unlikely since neither neonatology
nor radiology staff physicians changed during the study
period; furthermore, diagnostic criteria in the database
remained constant. However, over the last decade there
has been an increase in the incidence of NEC in a
nationally representative sample of NICUs, and our
observation may reflect this background trend [31].
Since this study compares two historical cohorts, it is
p o s s i b l et h a tu n m e a s u r e dc o n f o u n d e r sm a yh a v ec h a n -
ged over time, and affected the primary or secondary
study outcomes. However, in our NICU, indomethacin
and ibuprofen were used for treatment of PDA during
two immediately contiguous eras. Because the switch in
management occurred through mutual agreement of all
neonatologists, indomethacin was exclusively used
before October 2006 and ibuprofen thereafter. In our
analysis we excluded the few patients who received both
indomethacin and ibuprofen. The study comprises only
a 4 year time span, so the effects of therapeutic drift
should be minimal; furthermore, there were no other
planned or perceived changes in clinical management
related to PDA.
The larger number of patients evaluated in this study
increased our ability to detect important differences in
adverse events between the two drugs. Most of the pre-
vious studies, both retrospective and prospective, had
lower numbers of patients enrolled [5,11,14,16,23,29].
The retrospective nature of the study facilitated observa-
tion of the effects of both indomethacin and ibuprofen
during unrestricted clinical usage. In particular, we
demonstrated the consequences of repeated courses of
cyclooxygenase inhibitor treatment in a large cohort of
ELBW neonates.
This study confirms the findings or prior trials, reveal-
ing comparable effectiveness of indomethacin and ibu-
profen in closing a PDA [11,13,21-23]. It also adds
substantial weight to the notion that the likelihood of
successful medical closure of the PDA diminishes with
each subsequent course [27].
A limitation of our study is that it was retrospective.
This allowed for some variability in treatment
approaches by attending neonatologists; however, all
clinicians used the same dosage regimen of PDA therapy
and had similar approaches to PDA diagnosis. There
was a wide range in the gestational age as well as acuity
level of the neonates, which allows the results of this
s t u d yt ob em o r eb r o a d l yg e n e r a l i z a b l e .T h el a r g e rp r o -
portion of males in the ibuprofen era is likely a chance
finding, since review of our data on more than 1900
VLBW newborns over 14 years did not reveal a gender
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ligations. Furthermore, theg e n d e rd i f f e r e n c eb e t w e e n
our study groups is unlikely to influence the results,
since we found no gender-related differences in indices
of renal function at baseline or in changes in urine out-
put or creatinine during treatment courses.
Conclusion
In summary, our data indicated that both indomethacin
and ibuprofen appear to have a similar overall effect on
renal function, particularly with repeated courses of ther-
apy. This effect may be clinically apparent with decreased
urine output and potential fluid overload, and it is more
prominent during the first course of indomethacin.
Whereas a decrease in urine output of nearly 10 mL/kg/
day may be anticipated during the first course of indo-
methacin therapy for PDA, both indomethacin and ibu-
profen will produce a decrease in urine output of about
20 mL/kg/day during subsequent courses. These changes
in renal function should be considered and reflected in
fluid and electrolyte management by prospectively
decreasing fluid intake by approximately 20 mL/kg/day,
especially if treatment is required beyond one course.
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